Germany’s strict product price controls will continue to exert downward pressure on pharmaceutical spending in the next few years. There are also concerns that the Russia/Ukraine crisis and the effect of current and potential sanctions may place economic stress on European Union countries (many of which are still recovering from the Eurozone crisis). That stress may constrain future health insurance contributions and hence care spending and lead to even more stringent pharmaceutical price controls.

In terms of pharmaceutical production, Germany is the second-largest market in Europe, after Switzerland. Although German life sciences companies generally sat out several recent rounds of sector consolidation, some are now considering M&A as a way to offset the growth of generics, replenish their product pipelines with innovative formulations, and extend into new geographic and demographic markets. One downside of this approach: The larger the resulting company, the harder it can be to move into product and geographic markets that may require different development and commercialization models.

To operate successfully in Germany’s cost-conscious healthcare market, life sciences companies will need to focus on developing (or acquiring) solutions that address both biological illness and real-world care challenges; consider adopting innovative market access models; and solve the problem of unsustainable pricing (extremely high-priced innovations) that will likely elicit a defensive response from payors and health care systems.

---

1 I Industry Report, Healthcare: France, The Economist Intelligence Unit, June 2014
2 Industry Report, Healthcare: Germany, The Economist Intelligence Unit, June 2014
3 Ibid
4 Ibid
Dr. Gregor-Konstantin Elbel, MD PhD
LSHC Industry Leader
Deloitte Germany
+49 211 8772 3104
gelbel@deloitte.de

To learn more about the global trends and issues impacting the life sciences sector, please visit our 2015 global life sciences sector outlook at www.deloitte.com/2015lifesciencesoutlook.